KESTRA MEDICAL TECHNOLOGIES
KMTSNASDAQTrading Snapshot
- Day Range
- $28.29 – $28.78
- 52-Week Range
- $17.34 – $30.00
- Volume
- $3.57B
- Avg Volume
- $4.50B
- Shares Outstanding
- 58.6M
- Next Earnings
- Dec 15, 2026
Fundamentals Snapshot
- Annual Revenue
- $95M
- Last Q Revenue
- $31M
- P/E Ratio
- —
- P/S Ratio
- 15.7x
- EPS (TTM)
- $-2.67
- Dividend Yield
- —
- Dilution (1yr)
- +14.0%
Why Investors Own KMTS
- ✓High-growth profile — revenue up +54.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 38% gross margin and 20% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
KESTRA MEDICAL TECHNOLOGIES
KMTS
StockOtter · stockotter.spaceAbout KESTRA MEDICAL TECHNOLOGIES
Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
KESTRA MEDICAL TECHNOLOGIES tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift KMTS price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
KESTRA MEDICAL TECHNOLOGIES announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.